Abbreviations: AMPK, 5' adenosine monophosphate-activated protein kinase; Atg, autophagy-16 related protein; LC3, microtubule-associated protein light chain 3; mTOR, mammalian target of 17 rapamycin; NFκB, nuclear factor kappa beta; PARP, poly (ADP-ribose) polymerase. 
Introduction

1
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer deaths worldwide [1] .
2
The clinical benefit of platinum-based chemotherapy in advanced NSCLC has reached a plateau 3 [2, 3]. Epidermal growth factor receptor (EGFR) is frequently deregulated [4, 5] or 4 overexpressed [6] in NSCLC. The EGFR downstream signaling pathways are pivotal in the 5 initiation and progression of cancers, serving as one of the key therapeutic targets in NSCLC [7] . 6 Erlotinib, as one of the prototypical EGFR tyrosine kinase inhibitors (TKIs), has been approved 7 by U.S. Food and Drug Administration (FDA) for treatment of NSCLC [8] [9] [10] , however, La Jolla, Southern California, USA). A p-value < 0.05 was taken as statistically significant. was only evident in HCC827 and HCC4006 cells (sensitive) (Fig. 1A) , but not in H358 and
12
H1975 cells (resistant) (Fig. 1B) . Similarly, autophagic flux was observed in sensitive NSCLC H1975 cells (Fig. 1D, E, F, G) . The conjugation of Atg5/Atg12 increased in a time-dependent 21 manner when HCC827 and HCC4006 cells were treated with erlotinib (Fig. 1H) . Finally, p62
22
was degraded in a time-dependent manner after erlotinib exposure in HCC827 and HCC4006 23 cells (Fig. 1I) . Taken together, these findings provided strong evidence that erlotinib induced 1 autophagy in sensitive NSCLC cells. accompanied by the p53 translocation from cytosol to nucleus ( Fig. 2A and 2B ), AMPK 7 activation through up-regulation of p-AMPK (Thr172) (Fig. 2C ), p-NFkB activation (Fig. 2D) 8
and down-regulation of p-mTOR (ser2448) (Fig. 2E ) after erlotinib treatment (0.2 μM) in both
9
HCC827 and HCC4006 cells. 
Inhibition of autophagy enhanced pro-apoptotic effects of erlotinib in sensitive NSCLC cells
12
To investigate whether inhibition of autophagy would affect the cytotoxicity of erlotinib,
13
NSCLC cells were treated with erlotinib in the presence of 10 µM chloroquine (autophagy 14 inhibitor). The concentration of chloroquine was chosen that did not cause significant cell death
15
(data not shown), but was sufficient to inhibit autophagy as shown by accumulation of LC3-II
16
( Fig. 3A) . Based on cell viability assay using crystal violet staining, the combination of 17 chloroquine and erlotinib significantly decreased cell viability compared to erlotinib alone in 18 sensitive NSCLC cells, but not in the resistant cell lines H358 and H1975 (Fig. 3B) . Similarly,
19
addition of chloroquine to erlotinib increased the percentage of apoptotic cells in sensitive
20
NSCLC cells, but not in resistant cells (Fig. 3C and Table 1 ). Furthermore, the cleavage of PARP 21 was also enhanced in the presence of chloroquine in the sensitive cells (Fig. 3D) . significance of autophagy as a resistance mechanism to EGFR TKI.
6
In conclusion, autophagy can be induced upon exposure to clinically relevant concentrations of There is no funding source to declare. No writing assistance was sought in the preparation of this 8 report.
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